HLN Haleon plc Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
04:44
Aug 11
Aug 11
Berenberg raises its target price for Hikma Pharmaceuticals to 2,100 pence from 1,800 pence.
Berenberg raises its target price for Hikma Pharmaceuticals to 2,100 pence from 1,800 pence, reflecting an upgraded valuation outlook.
06:23
Aug 10
Aug 10
Deutsche Bank raises its target price for Hikma Pharmaceuticals to 2,050 pence from 1,950 pence.
Deutsche Bank raises its target price for Hikma Pharmaceuticals to 2,050 pence from 1,950 pence, reflecting a modestly improved outlook.
11:21
Jul 30
Jul 30
Long Haleon on Sensodyne-driven margin expansion
Haleon is delivering accelerating organic sales growth (3.1%), improving margins from its productivity program, and Sensodyne continues to outperform. The US is showing a step change in execution, and the company reiterated strong full-year guidance.
MED
About HLN Investor Commentary
Across the available history and selected sources, Buzzberg tracks HLN (Haleon plc) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: FirstSquawk, Brian McNamara.